Hologic, Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 9,282 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Hologic, Inc. (NASDAQ HOLX) traded up $0.24 during midday trading on Friday, reaching $39.96. The company had a trading volume of 2,092,406 shares, compared to its average volume of 2,739,979. Hologic, Inc. has a 12-month low of $35.76 and a 12-month high of $46.80. The stock has a market cap of $11,140.00, a P/E ratio of 19.61, a P/E/G ratio of 1.92 and a beta of 0.93. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.78.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 EPS. Hologic’s quarterly revenue was up 10.5% on a year-over-year basis. equities research analysts anticipate that Hologic, Inc. will post 2.12 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Director Elaine Ullian Sells 9,282 Shares” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/17/hologic-inc-holx-director-elaine-ullian-sells-9282-shares.html.

A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, October 31st. Needham & Company LLC reissued a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Friday, November 3rd. BidaskClub downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Bank of America Corporation reissued a “neutral” rating and set a $48.00 target price (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $45.00 target price (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. Hologic currently has an average rating of “Buy” and an average target price of $47.54.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC purchased a new position in Hologic in the 3rd quarter valued at approximately $554,000. IFM Investors Pty Ltd purchased a new position in Hologic during the third quarter worth $335,000. Ladenburg Thalmann Financial Services Inc. increased its position in Hologic by 66.4% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock worth $458,000 after buying an additional 4,984 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in Hologic by 249.1% during the third quarter. Cubist Systematic Strategies LLC now owns 48,878 shares of the medical equipment provider’s stock worth $1,793,000 after buying an additional 34,877 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Hologic during the third quarter worth $39,041,000. 96.41% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.